Product Information
PRADAXA 75 MG CAPSULE is a brand product labeled by Boehringer Ingelheim Pharmaceuticals Inc., priced at $3.1670 per EA under NDC 00597035556. Its NADAC has been published 447 times since Mar 14, 2018.
FDA first approved this application on Oct 19, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
75 mg/1
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc.NDC
00597035556
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DABIGATRAN ETEXILATE MESYLATEApproval Type
New Drug (NDA)
FDA Application
NDA022512FDA Approved
10/19/2010
TE Code
AB
On Market Since
8/8/2011
Pharmacological Classes
Price Statistics
The NADAC for PRADAXA 75 MG CAPSULE has been published 447 times since Mar 14, 2018, and over the history we have for it it has declined 50.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.1670 per EA |
|---|---|
| All-time high | $7.9382 (Jun 28, 2023) |
| All-time low | $3.1576 (Jul 22, 2026) |
| 52-week high | $3.1679 |
| 52-week low | $3.1576 |
| Median price | $6.9000 |
| Average price | $5.7471 |
| Largest weekly change | -60.0% (Jul 5, 2023) |
| Weeks tracked | 447 |
| Tracking since | Mar 14, 2018 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Boehringer Ingelheim Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dabigatran etexilate mesylate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Direct Thrombin Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PRADAXA 75 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PRADAXA 75 MG CAPSULE, manufactured by Boehringer Ingelheim Pharmaceuticals Inc., is $3.1670 per EA (NDC 00597035556), effective Sep 30, 2026.
How has the price of PRADAXA 75 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PRADAXA 75 MG CAPSULE has declined 50.6%. It has been tracked across 447 weekly CMS publications since Mar 14, 2018.
What are the highest and lowest recorded NADAC prices for PRADAXA 75 MG CAPSULE?
Since Mar 14, 2018, the NADAC for PRADAXA 75 MG CAPSULE has ranged from a low of $3.1576 (Jul 22, 2026) to a high of $7.9382 (Jun 28, 2023), with a median of $6.9000 per EA.
Are there cheaper alternatives to PRADAXA 75 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PRADAXA 75 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures PRADAXA 75 MG CAPSULE?
PRADAXA 75 MG CAPSULE (NDC 00597035556) is labeled by Boehringer Ingelheim Pharmaceuticals Inc., and CMS classifies it as a brand product.